BRAF and colorectal carcinoma: We considered this finding of worth to be followed-up since previous experimental studies, which did not specifically focus on the subgroup of MSI CRCs, had suggested that vemurafenib is apparently much less efficient in BRAF mutant CRC than in malignant melanoma [14].